Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

References

• Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2013. Toronto, ON: Canadian Cancer Society, 2013. http://www.cancer.ca/en/cancer-information/cancer-type/colorectal/statistics/. Accessed June 2013
   Google Scholar
• Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON: Canadian Cancer Society, 2011
   Google Scholar
• Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2009_pops09/, based on November 2011 SEER data submission, posted to the SEER website, 2012. Accessed August 2013
   Google Scholar
• Benson AB 3rd, Bekaii-Saab T, Chan E, et al. Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013;11:141-52
   PubMed Web of Science ®Google Scholar
• Jonker D, Biagi J, Haynes AE. The use of epidermal growth factor receptor inhibitors in advanced colorectal cancer. Toronto (ON): Cancer Care Ontario; 2008 Jul 9 [Archived 2012]. Program in Evidence-based Care CED-CCO Special Advice Report No.: 8 Archived
   Google Scholar
• British Columbia Cancer Agency. Cancer Management Guidelines: Colon. Treatment Options by Stage Based on Current Evidence. Revised 05 Sept 2012 Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/Gastrointestinal/05.Colon/5.6+Treatment+Options+by+Stage+Based+on+Current+Evidence.htm. [Last accessed August 2013]
   Google Scholar
• Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEJM 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-9
   PubMed Web of Science ®Google Scholar
• Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-705
   PubMed Web of Science ®Google Scholar
• ImClone LLC. Erbitux Product Monograph. 2012
   Google Scholar
• Hurwitz H, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14:22-8
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Z, Barber B, et al. Cost of illness in patients with metastatic colorectal cancer. J Med Econ 2011;14:1-9
   PubMedGoogle Scholar
• Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edn. Ottawa: Government of Canada, 2006
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
   Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-37
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-86
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier PL. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;56:457-81
   Google Scholar
• Statistics Canada. CANSIM Table 326-0021. Consumer Price Index (CPI), 2009 basket. Ottawa: Government of Canada, 2013. Available at: http://www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=3260021&pattern=326-0020..326-0022&tabMode=dataTable&srchLan=-1&p1=-1&p2=31. [Last accessed 20 February 2012]
   Google Scholar
• Cancer Care Ontario. Cancer Care Ontario Drug Formulary. 2011. Available at: https://www.cancercare.on.ca/toolbox/drugs/drugformulary/. [Last accessed November 2011]
   Google Scholar
• British Columbia Cancer Agency. Chemotherapy Protocols: Gastrointestinal. 2011. Available at: http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/default.htm. [Last accessed November 2011]
   Google Scholar
• Dranitsaris G, Truter I, Lubbe MS, et al. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs. J Eval Clin Pract 2012;18:343–51
   Google Scholar
• Hoffmann-La Roche Limited. Data on file. 2012
   Google Scholar
• Hoffmann-La Roche Limited. Avastin Product Monograph. 2012
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index. 2012. Available at: www.healthinfo.moh.gov.on.ca/formulary/index.jsp. [Last accessed January 2012]
   Google Scholar
• Régie de l'assurance maladie du Québec. List of Medications. Last Updated on 16 December 2011. Available at: www.prod.ramq.gouv.qc.ca. [Last accessed January 2012]
   Google Scholar
• Ontario Case Costing Initiative. Ontario guide to case costing. Province of Ontario, Canada: Ministry of Health and Long-Term Care, 2012. Available at: www.occp.com/mainPage.htm. [Last accessed February 2012]
   Google Scholar
• Ontario Ministry of Health and Long-Term Care. Schedule of Benefits: Physician Services under the Health Insurance Act. Ontario: 2012. Available at: www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/a_consul.pdf [Last accessed January 2012]
   Google Scholar
• CanadaDrugs.com. 2012. Available at: www.canadadrugs.com. [Last accessed January 2012]
   Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14:29-37
   PubMed Web of Science ®Google Scholar
• Petrou S, Campbell N. Stabilisation in colorectal cancer. Int J Palliat Nurs 1997;3:275-80
   PubMedGoogle Scholar
• SAS Institute Inc. SAS/STAT® 9.2 User's Guide, Second Edition. The LIFETEST Procedure: Pointwise Confidence Limits in the OUTSURV= Data Set. Cary, NC: SAS Institute Inc. 2009. http://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/viewer.htm#statug_lifetest_a0000000262.htm. [Last accessed 14 June 2012]
   Google Scholar
• Asseburg C, Frank M, Köhne CH, et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther 2011;33:482-97
   PubMed Web of Science ®Google Scholar